References

Albert A. Chemical aspects of selective toxicity. Nature 1958; 182:421-423

Albert A. Selective Toxicity: The Physico-Chemical Basis of Therapy. 7th edition. New York, NY: Chapman and Hall; 1985. pp.97-109, pp. 208-214

Anon. Lexiva (fosamprenavir calcium) tablets. Prescribing information. GlaxoSmithKline and Vertex. 2003; 1-36

Balimane, P. V, I. Tamai, A. Guo, T. Nakanishi, H. Kitada, F. H. Leibach, A. Tsuji and P. J. Sinko. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Com. 1998; 250: 246-251

Beauchamp, L. M., G. F. Orr, P. De Miranda, T. Burnette and T. A. Krenitsky. Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. 1992; 3: 57-64

Bentley A, Butters M, Green SP, Learmonth WJ, MacRae JA, Morland MC, O'Connor G, and Skuse J. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole. Org. Process Res. Dev. 2002; 6:109-112

Bernardelli P, Gaudilliere B, and Vergne F: To Market, to Market - 2001. Ann. Rep. Med. Chem. 2002; 37:257-277

Bito LZ, Draga A, Blanco J, and Camras CB. Long-term maintenance of reduced intraocular pressure by daily twice daily topical application of prostaglandins to cat of rhesus monkey eyes. Invest. Ophthalmol. Vis. Sci. 1983; 24:312-319

Bito LZ. Prostaglandins, old concepts and new perspectives. Arch. Ophthalmol. 1987; 105:1036-1039

Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev. 2002; 54:589-598

Bundgaard H. Design of Prodrugs. Amsterdam: Elsevier; 1985

Bundgaard H. (Ed), Themed issue. Prodrugs for Improved Drug Delivery. Adv. Drug Del. Rev. 1989; 3:1-154

Denny WA. Prodrug Strategies in Cancer Therapy. Eur. J. Med. Chem. 2001; 36: 577-595

Denny WA. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J. Biomed. Biotech. 2003:48-70

Doherty AM. To Market, to Market - 2002. Ann. Rep. Med. Chem. 2003; 38: 347-374

Elger W, Schwarz S, Hedden A, Reddersen G, and Schneider B. Sulfamates of Various Estrogens are Prodrugs with Increased Systemic and Reduced Hepatic Estrogenicity at Oral Application. J. Steroid Biochem. Mol. Biol.. 1995; 55:395-403

Elger W, Palme H-H, and Schwarz S. Novel Oestrogen Aulfamates: A New Approach to Oral Hormone Therapy. Exp. Opin. Invest. Drugs 1998; 7:575-589

Fechner J, Ihmsen H, Hatterscheid D, Schiessi C, Vornov, JJ, Burak E, Schwilden H, and Schuttler J. Pharmacokinetics and Clinical Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Volunteers. Anesthesiol. 2003; 99: 303-313

Ferres H. Pro-Drugs of ,-Lactam Antibiotics. Drugs of Today 1983; 19:499-538

Fleisher D, Stewart B, and Amidon GL. Design of prodrugs for Improved Gastrointestinal Absorption by Intestinal Enzyme Targeting. Methods Enzymol. 1985; 112:360-381

Glazko AJ, Carnes HE, Kazenk A, Wolf LM, and Reutner TF. Succinic Acid Esters of Chloramphenicol. Antibiot. Annu. 1957-58; 792-802

Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, and Bylund R. The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects. Thromb Res. 2001; 101:171-181

Gustafsson D. Oral Direct Thrombin Inhibitors in Clinical Development. J. Intern. Med. 2003; 254: 322-334

Hale MR, Tung RD, Baker CT, and Spaltenstein A, Prodrugs of Aspartyl Protease Inhibitors. US patent #6,436,989, August 20, 2002

Han, H.-K., R. L. A. De Vrueh, J. K. Rhie, K.-M. Y. Covitz, P. L. Smith, C.-P. Lee, D.-M. Oh, W. Sadee and G. L. Amidon. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998; 15 : 1154-1159

Harper NJ. Drug Latentiation. J. Med. Pharm. Chem. 1959; 1:467-500

Harper NJ. Drug Latentiation. Prog. Drug Res. 1962; 4:221-294

Heimbach T, Oh DM, Li LY, Forsberg M, Savolainen J, Leppanen J, Matsunaga Y, Flynn G, and Fleischer D. Absorption Rate Limit Considerations for Oral Phosphate Prodrugs. Pharm. Res. 2003; 20:848-856

Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, and Graff G. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J. Ocul. Pharmacol. Ther. 2003; 19:97-103

Higuchi T, and Stella V Pro-drugs as Novel Drug Delivery Systems. Washington DC. ACS Symposium Series #14, American Chemical Society; 1975

Horspool KR, Lipinski CA. Enabling Strategies: Advancing New Drug Delivery Concepts to Gain the Lead. Drug Del. Tech. 2003; 3(7): 34-46

Ikeda S, Sakamoto F, Kondo H, Moriyama M and Tsukamoto G. Studies on Prodrugs. III. A Convenient and Practical Preparation of Ampicillin Produgs. Chem. Pharm. Bull. 1984; 32:4316-4322

Johnson P. Pro-drugs and First-Pass Effects. Chem. Ind. 1980; June 7:443-447

Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43:595-612

Kondo A, Sakamoto F, Uno T, Kawahata Y, and Tsukamoto G. Studies on Prodrugs 11. Synthesis and Antimicrobial Activity of N-[4-Methyl-5-methylene-2-oxo-1,3-dioxolan-4-yl)oxy]norfloxacin. J. Med. Chem. 1989; 32;671-674

Krise JP, and Stella VJ. Prodrugs: A Year of Renewed Interest in an Old Concept.

AAPS Newsmagazine. 2003; December:25

Lee P-Y, Shao H, Xu L, and Qu C-K. The effect of prostaglandin F2 ? on intraocular pressure in normotensive human subjects. Invest. Ophthalmol. Vis. Sci. 1988; 29:1474-1477

Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB. Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071. Antimicrob Agents Chemother. 1998; 42:647-53

Lipinski CA. Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. J. Pharmacol. Toxicol. Meth. 2000; 44: 235-249

Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Del. Rev. 1997; 23: 3-25

Martin JC., Tippie MA, McGee DPC and Verheyden JPH, Synthesis and antiviral activity of various esters of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. J. Pharm. Sci. 1987; 76; 180-184

Maxey KM, Johnson JL, and LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv. Ophthalmol. 2002; 47:S34-40

Nahata MC. and Powell DA. Bioavailability and Clearance of Chloramphenicol after Intravenous Chloramphenicol Succinate. Clin. Pharmacol. Ther. 1981; 30:368-372

Narisawa S, and Stella VJ. Increased Shelf-Life of Fosphenytoin: Solubilization of a Degradant, Phenytoin, through Complexation with (SBE)7M-,-CD. J. Pharm. Sci. 1998; 87:926-930

Roche EB. Design of Biopharmaceutical Properties Through Prodrugs and Analogs. Washington, DC: American Pharmaceutical Association; 1977

Rosenberg IH. Intestinal Absorption of Folate. In: Johnson LR. Physiology of the Gastrointestinal Tract. Raven Press, New York, NY 1981; Vol. 2:1221-1230

Sakamoto F, Ikeda S, and Tsukamoto G. Studies on Prodrugs II. Preparation and Characterization of (5-Substituted 2-Oxo-1,3-dioxolen-4-yl)methyl Esters of Ampicilllin. Chem. Pharm. Bull. 1984; 32;2241-2248

Schywalsky M, Ihmsen H, Tzabazis A, Fechner J. Burak E. Vornov J, and Schwilden H. Pharmacokinetics and Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Rats. Eur. J. Anesthesiol. 2003; 20: 182-190

Seddon B, Kelland LR, and Workman P. Bioreductive Prodrugs for Cancer Therapy. Methods Mol. Med. 2004; 90:515-542

Sharif NA, Kelly CR, Crider JY, Williams GW, and Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 2003; 19:501-15

Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, and Cundy KC. Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl] Adenine (PMPA) in Dogs. Pharm. Res. 1997; 14:1824-1829

Shen T-S, and Winter CA. Chemical and Biological Studies on Indomethacin, Sulindac and Their Analogs. Adv. Drug Res. 1977; 12;89-246

Sinkula AA. Prodrug Approach in Drug Design. Ann. Rep. Med. Chem. 1975; 10:306-316

Sinkula AA, and Yalkowsky SJ. Rationale for the Design of Biologically Reversible Derivatives: Prodrugs. J. Pharm. Sci. 1975; 64:181-210

Sloan KB. Prodrugs: Topical and Ocular Drug Delivery. New York, NY: Marcel DekkerInc; 1992

Stella VJ. Themed issue. Low molecular weight prodrugs. Adv. Drug Del. Rev. 1996a; 19:111-330

Stella VJ. Preface. Adv. Drug Del. Rev. 1996b; 19:111-114

Stella VJ. A Case for Prodrugs, Fosphenytoin, Adv. Drug Del. Rev. 1996c; 19:311-330

Stella VJ. Prodrugs as Therapeutics. Exp. Opin. 2004; 14:277—280

Stella VJ, Zygmunt JJ, Georg IG, and Safadi MS. Water Soluble Prodrugs of Hindered Alcohols. US patent #6,204,257, March 20, 2001

Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V and Ganapathy ME, Transport of valganciclovir, a ganciclovir prodrug , via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 2000; 89; 781-789

Svensson LA, and Tunek A. The Design and Bioactivation of Presystemically Stable Prodrugs. Drug Metab Rev. 1988; 19:165-194

Ueda Y, Matiskella JD, Golik J, Connolly TP, Hudyma TW, Ventaesh S, Dali M, Kang S-H, Barbour N, Tejwani R, Varia S, Knipe J, Zheng M, Mathew M, Mosure K, Clark J, Lamb L, Medin I, Gao Q, Huang S, Chen C-P, and Bronson JJ. Phosphonooxym ethyl Prodrugs of the Broad Spectrum Antifungal Azole, Ravuconazole: Synthesis and Biological Properties. Bioorg. Med. Chem. Lett. 2003; 13:3669-3672

Wermuth CG. Designing prodrugs and bioprecursors. In: Wermuth CG. Practice of Medicinal Chemistry. Academic Press, London, UK 1996; pp. 697-715. An earlier version of this paper also appeared in 1984 in Drug Design: Fact or Fantasy by the same publisher.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment